As an example, pharmacologic intervention with anti-diabetic drugs such as sodium glucose cotransporter 2 (SGLT2) inhibitors have the ability to potentially directly inhibit tumor glucose metabolism at the same time as reducing visceral fat [50,51,52,53]. This evidence concerns the gene SLC5A2 and neoplasm.